Use of ocular hypotensive prostaglandin analogues in patients with uveitis: Does their use increase anterior uveitis and cystoid macular oedema?

British Journal of Ophthalmology

Volumn 92, Issue 7, 2008, Pages 916-921

  Chang, J H ^a,b,c   McCluskey, P ^b,c   Missotten, T ^a   Ferrante, P ^a   Jalaiudin, B ^b   Lightman, S ^a  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

^b LIVERPOOL HOSPITAL   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIMATOPROST; CARBONATE DEHYDRATASE INHIBITOR; CYCLOSPORIN A; LATANOPROST; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROSTAGLANDIN DERIVATIVE; STEROID; TRAVOPROST; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG WITHDRAWAL; EYE IRRITATION; FEMALE; FISHER EXACT TEST; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE ABNORMALITY; IRIDOCYCLITIS; MAJOR CLINICAL STUDY; MALE; PATIENT REFERRAL; PRIORITY JOURNAL; RETINA MACULA CYSTOID EDEMA; SCHOOL CHILD; STATISTICAL SIGNIFICANCE; TERTIARY HEALTH CARE; TREATMENT DURATION; UVEITIS;

ADOLESCENT; ADULT; AGED; ANTIHYPERTENSIVE AGENTS; CHILD; FEMALE; HUMANS; MACULAR EDEMA; MALE; MIDDLE AGED; OCULAR HYPERTENSION; PROSTAGLANDINS, SYNTHETIC; RETROSPECTIVE STUDIES; UVEITIS; UVEITIS, ANTERIOR;

EID: 47049099670     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2007.131037     Document Type: Article

References (27)

1. Herbert HM, Viswanathan A, Jackson H, et al. Risk factors for elevated intraocular pressure in uveitis. J Glaucoma 2004;13:96-9.
2. Chang JH, McCluskey PJ, Wakefield D. Acute anterior uveitis and HLA-B27. Surv Ophthalmol 2005;50:364-88.
3. van der Valk R, Webers CA, Schouten JS, et al. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology 2005;112:1177-85.
4. Camras CB, Aim A, Watson P, et al. Latanoprost, a prostaglandin analog, for glaucoma therapy: Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups. Ophthalmology 1996;103:1916-24.
5. Parrish RK, Palmberg P, Sheu WP. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 2003;135:688-703.
6. Stjemschantz JW, From PGF(2alpha)-isopropyl ester to latanoprost: a review of the development of xalatan: the Proctor Lecture. Invest Ophthalmol Vis Sci 2001;42:1134-45.
7. Wand M, Shields BM. Cystoid macular edema in the era of ocular hypotensive lipids. Am J Ophthalmol 2002;133:393-7.
8. Fechtner RD, Khouri AS, Zimmerman TJ, et al. Anterior uveitis associated with latanoprost. Am J Ophthalmol 1998;126:37- 41.
9. Warwar RE, Bullock JD, Ballal D. Cystoid macular edema and anterior uveitis associated with latanoprost use: Experience and incidence in a retrospective review of 94 patients. Ophthalmology 1998;105:263-8.
10. Moroi SE, Gottfredsdottir MS, Schteingart MT, et al. Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension. Ophthalmology 1999;106:1024-9.
11. Schumer RA, Camras CB, Mandahl AK. Latanoprost and cystoid macular edema: is there a causal relation? Curr Opin Ophthalmol 2000;11:94-100.
12. Linden C, Nuija E, Aim A. Effects on IOP restoration and blood-aqueous barrier after long-term treatment with latanoprost in open angle glaucoma and ocular hypertension. Br J Ophthalmol 1997;81:370-2.
13. Ziai N, Dolan JW, Kacere RD, et al. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol 1993;111:1351-8.
14. Hoyng PF, Rulo AH, Greve EL, et al. Fluorescein angiographic evaluation of the effect of latanoprost treatment on blood-retinal barrier integrity: a review of studies conducted on pseudophakic glaucoma patients and on phakic and aphakic monkeys. Surv Ophthalmol 1997;41(Suppl 2):83-8S.
15. Jabs DA, Nussenblatt RB, Rosenbaum JT, et al. Standardization of uveitis nomenclature for reporting clinical data: Results of the First International Workshop. Am J Ophthalmol 2005;140:509-16.
16. Becker HI, Walton RC, Diamant Jl, et al. Anterior uveitis and concurrent allergic conjunctivitis associated with long-term use of topical 0.2% brimonidine tartrate. Arch Ophthalmol 2004;122:1063-6.
17. Miyake K, Ota I, Ibaraki N, et al. Enhanced disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macular edema by topical timolol and its preservative in early postoperative pseudophakia. Arch Ophthalmol 2001 ;119:387-94.
18. Akingbehin T, Villada JR. Metipranolol-associated granulomatous anterior uveitis. Br J Ophthalmol 1991;75:519-23.
19. Jabs DA. Improving the reporting of clinical case series. Am J Ophthalmol 2005;139:900-5.
20. Watson P, Stjemschantz J. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. Ophthalmology 1996;103:126-37.
21. Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning: A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology 1995;102:1743-52.
22. Camras CB. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology 1996;103:138-47.
23. Miyake K, Ota I, Maekubo K, et al. Latanoprost accelerates disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macular edema in early postoperative pseudophakias. Arch Ophthalmol 1999;117:34-40.
24. Furuichi M, Chiba T, Abe K, et al. Cystoid macular edema associated with topical latanoprost in glaucomatous eyes with a normally functioning blood-ocular barrier. J Glaucoma 2001;10:233-6.
25. Camras CB. CME and anterior uveitis with latanoprost use. Ophthalmology 1998;105:1978-81.
26. Wand M, Gaudio AR, Shields MB. Latanoprost and cystoid macular edema in high-risk aphakic or pseudophakic eyes. J Cataract Refract Surg 2001;27:1397-401.
27. Neri P, Azuara-Blanco A, Forrester JV. Incidence of glaucoma in patients with uveitis. J Glaucoma 2004;13:461-5.